

~ Updates on HPMS Memos ~

CMS Email Title & Release Date	Medicare Part C Reporting Requirements for 2022 Contract Year (CY) – Dated 01/20/2022
Summary	CMS announced OMB approval of the 2022 Part C Reporting Requirements. A link to the current documents is provided.
Action	Informational to PACE, as PACE is excluded from Part C reporting requirements.
CMS Memo Title & Release Date	Part D Drug Management Program (DMP) – Revised Standardized Beneficiary Notices, Model Documents, and Instructions – Dated 01/14/2022
Summary	Effective Thursday, April 7, 2022 sponsors must use approved, standardized beneficiary notices, and <u>may not develop their own writing</u> with beneficiaries for whom they intend to limit access to coverage under a DMP. The revised notices contain updated language incorporating legislative and regulatory changes for DMPs, clarifications, and other improvements. Refer to the memo for the link to the standardized beneficiary notices and instructions.
Action	Applicable to PACE.
CMS Memo Title & Release Date	CY 2023 Plan Benefit Package (PBP) Testing – Dated 01/14/2022
Summary	CMS is conducting beta testing to ensure all aspects of the CY 2023 PBP software work as designed, and requests assistance from plans in the final testing of the CY 2023 PBP. Testing will take place from Monday, January 24, 2022 through Friday, February 4, 2022 . A link to download the CY 2023 PBP beta software is provided.
Action	Informational to PACE. Refer to the memo for complete details.
CMS Memo Title & Release Date	Coronavirus Disease 2019 (COVID-19) Permissive Actions Extended in CY 2022 – Dated 01/14/2021
Summary	This memo is to inform Medicare Advantage Organizations (MAOs), Part D sponsors, and Medicare-Medicaid Plans (MMPs) that CMS will extend the flexibilities in CY 2022. Refer to memo for further details on FAQs and guidance.
Action	Applicable to PACE.

CMS Memo Title & Release Date	Prescription Drug Event (PDE) Guidance Related to Oral Antiviral Drugs for Treatment of COVID-19 – Dated 01/20/2022
Summary	This memo provides the following instruction with regard to PDE reporting of dispensing fees associated with Emergency Use Authorization (EUA) oral antiviral drugs, as well as other information related to PDE reporting.
Action	Applicable to PACE.
CMS Email Title & Release Date	CY 2022 Part D Reporting Requirements: Office of Management and Budget’s (OMB) Approval – Dated 01/21/2021
Summary	CMS announces the OMB approval of the 2022 Part D Reporting Requirements. The CY 2022 Reporting requirements and Technical Specifications documents can be found on the HPMS Plan Reporting site. Refer to email for direct link .
Action	Informational to PACE, as PACE is excluded from Part D reporting requirements.
CMS Email Title & Release Date	Release of Updated CY 2022 Part D Baseline Out-of-Pocket Cost (OOPC) Model – Dated 01/21/2021
Summary	The purpose of this memo is to provide information about the OOPC Model to determine differences between plan offerings and by MAOs in calculating changes in Total Beneficiary Cost (TBC) from one year to the next. Refer to memo for further information and links.
Action	Informational to PACE, as PACE is waived of the OOPC requirements.
CMS Memo Title & Release Date	Part D Senior Savings Model Pharmaceutical Manufacturer Application Process for Plan Year (PY) 2023 – Dated 01/27/2022
Summary	CMS has released the CY 2023 Part D Senior Savings Model Pharmaceutical Manufacturer Request for Applications (RFAs) for PY 2023. Manufacturers who are not currently participating in the Model that wish to participate in the 2023 PY must submit a completed Addendum to CMS by 11:59 p.m. EST on Friday, February 4, 2022 EST . Links to the information and request for the applications are provided
Action	Informational to PACE.

For the latest CMS response to COVID-19, please visit the CMS.gov website.

Please note that this information is provided to you in summary form for general informational purposes only and does not constitute legal or regulatory compliance advice. It is your responsibility to consult with your Compliance Officer and/or legal counsel to determine applicability of any regulation or standards referenced herein to your organization and/or processes.